Original Paper

Clinical Reviews in Bone and Mineral Metabolism

, Volume 8, Issue 1, pp 15-26

Glucocorticoid-Induced Osteoporosis: A Review

  • Béatrice BouvardAffiliated withFaculté de Médecine, INSERM, U 922–LHEAService de Rhumatologie
  • , Erick LegrandAffiliated withFaculté de Médecine, INSERM, U 922–LHEAService de Rhumatologie
  • , Maurice AudranAffiliated withFaculté de Médecine, INSERM, U 922–LHEAService de Rhumatologie
  • , Daniel ChappardAffiliated withFaculté de Médecine, INSERM, U 922–LHEA Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Glucocorticoid (GC)-induced osteoporosis is the main cause of secondary osteoporosis. Fractures, which are often asymptomatic, can occur in as many as 50% of patients receiving chronic GC therapy. GCs have direct and indirect effects on bone cells (osteoblasts, osteocytes, and osteoclasts) with a suppression of bone formation and an increased bone resorption. The management of patients exposed to GCs should include the use of the minimal effective dose of GC, general health measures, and adequate intakes of calcium and vitamin D. Bisphosphonates are nowadays largely used in GC-induced osteoporosis and teriparatide has proved its efficiency as well.

Keywords

Glucocorticoid-induced osteoporosis Fractures Bone mineral density Microarchitecture Bone formation Bone resorption Bisphosphonates